Cross‐reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH‐AH 01/2010 Study

Background Recombinant porcine factor VIII (rpFVIII, OBI-1, susoctocog alfa) is used for the treatment of acute bleeds in patients with acquired hemophilia A (AHA). Inhibitors in AHA can sometimes cross-react with rpFVIII. Objectives To assess the frequency, strength, and determinants of cross-reactivity. Patients/methods Baseline samples from 70 patients of the prospective, observational cohort study GTH-AH 01/2010 were assessed for anti-human...